MSON has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MSON has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Misonix's Earnings per Share (Diluted) for the three months ended in Jun. 2021 was $-0.26. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.84.
Misonix's EPS (Basic) for the three months ended in Jun. 2021 was $-0.26. Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.84.
Misonix's EPS without NRI for the three months ended in Jun. 2021 was $-0.26. Its EPS without NRI for the trailing twelve months (TTM) ended in Jun. 2021 was $-0.84.
During the past 3 years, the average EPS without NRIGrowth Rate was 1.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -44.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Misonix's highest 3-Year average EPS without NRI Growth Rate was 169.20% per year. The lowest was -75.50% per year. And the median was 7.15% per year.
The historical data trend for Misonix's EPS (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Misonix Annual Data | |||||||||||||||||||||
Trend | Jun12 | Jun13 | Jun14 | Jun15 | Jun16 | Jun17 | Jun18 | Jun19 | Jun20 | Jun21 | |||||||||||
EPS (Diluted) | Get a 7-Day Free Trial | -0.20 | -0.85 | -0.79 | -1.19 | -0.84 |
Misonix Quarterly Data | ||||||||||||||||||||
Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | |
EPS (Diluted) | Get a 7-Day Free Trial | -0.50 | -0.29 | -0.07 | -0.22 | -0.26 |
For the Medical Devices subindustry, Misonix's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Misonix's PE Ratio distribution charts can be found below:
* The bar in red indicates where Misonix's PE Ratio falls into.
EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.
Misonix's Diluted EPS for the fiscal year that ended in Jun. 2021 is calculated as
Diluted EPS (A: Jun. 2021 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-14.473 | - | 0) | / | 17.226 | |
= | -0.84 |
Misonix's Diluted EPS for the quarter that ended in Jun. 2021 is calculated as
Diluted EPS (Q: Jun. 2021 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Diluted Average) |
= | (-4.473 | - | 0) | / | 17.247 | |
= | -0.26 |
EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.84
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Misonix (NAS:MSON) EPS (Diluted) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Misonix's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.
Paul A Laviolette | director | ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108 |
Sharon W Klugewicz | officer: Chief Operating Officer | 3661 HORSEBLOCK ROAD, MEDFORD NY 11763 |
Thomas M Patton | director | C/O OSTEOTCH INC., 51 JAMES WAY, EATONTOWN NJ 07724 |
Joseph P Dwyer | officer: Chief Financial Officer | 3 CORDWOOD COURT, E. NORTHPORT NY 11731 |
Gwendolyn A Watanabe | director | C/O SARATOGA VENTURES, 210 ALMENDRA AVENUE, LOS GATOS CA 95030 |
Linwood A. Staub | officer: Sr. VP Wound | 8023 VANTAGE DRIVE SAN ANTONIO TX 78230 |
Stavros G. Vizirgianakis | director, officer: CEO | 1/16-18 TENNYSON ST., WILLIAMSTOWN NORTH, VICTORIA CA 3016 |
Robert S Ludecker | officer: SVP Sales - Surgical | 4 WILDBRIAR COURT MOUNT SINAI NY 11766 |
Allan Richard Staley | officer: President | C/O SOLSYS MEDICAL, LLC 600 THIMBLE SHOALS BLVD., SUITE 200 NEWPORT NEWS VA 23606 |
Michael Koby | director | C/O 1315 CAPITAL 2929 WALNUT STREET, SUITE 1240 PHILADELPHIA PA 19104 |
1315 Capital Management, Llc | 10 percent owner | 2929 WALNUT STREET SUITE 1240 PHILADELPHIA PA 19104 |
Sv Life Sciences Fund Vi (gp), L.p. | 10 percent owner | ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108 |
Svlsf Vi, Llc | 10 percent owner | ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108 |
Sv Life Sciences Fund Vi Strategic Partners, L.p. | 10 percent owner | C/O SV LIFE SCIENCES ADVISERS, LLC, ONE BOSTON PLACE, SUITE 3900, BOSTON MA 02108 |
1315 Capital, L.p. | 10 percent owner | 3020 MARKET STREET, SUITE 104 PHILADELPHIA PA 19104 |
From GuruFocus
By Marketwired Marketwired • 10-20-2020
By Marketwired Marketwired • 11-23-2020
By Marketwired Marketwired • 12-23-2020
By GF Value GF Value • 05-21-2021
By Marketwired Marketwired • 06-15-2020
By Marketwired Marketwired • 05-14-2021
By Marketwired Marketwired • 01-21-2021
By Marketwired Marketwired • 05-10-2021
By Business Wire Business Wire • 07-31-2021
By Marketwired Marketwired • 07-30-2021
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.